98. Eosinophilic gastrointestinal disease
128 clinical trials,   147 drugs   (DrugBank: 40 drugs),   34 drug target genes,   132 drug target pathways
Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "N-FPIES"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04322708 (ClinicalTrials.gov) | July 6, 2020 | 24/3/2020 | A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis | A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis | Eosinophilic Esophagitis | Other: Placebo;Drug: lirentelimab (AK002) | Allakos, Inc. | NULL | Recruiting | 12 Years | 80 Years | All | 300 | Phase 2;Phase 3 | United States;Australia;Netherlands |
2 | NCT04322604 (ClinicalTrials.gov) | June 18, 2020 | 24/3/2020 | A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) | Eosinophilic Gastritis;Eosinophilic Duodenitis | Drug: lirentelimab (AK002);Other: Placebo | Allakos, Inc. | NULL | Recruiting | 18 Years | 80 Years | All | 160 | Phase 3 | United States |